Flegel, T.; Boettcher, I.C.; Matiasek, K.; Oevermann, A.; Doherr, M.G.; Oechtering, G.; Henke, D. (2011). Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs. Journal of the American Veterinary Medical Association, 238(3), pp. 337-45. Schaumburg, Ill.: American Veterinary Medical Association 10.2460/javma.238.3.337
Full text not available from this repository.OBJECTIVE: To compare oral administration of lomustine and prednisolone with oral administration of prednisolone alone as treatment for granulomatous meningoencephalomyelitis (GME) or necrotizing encephalitis (NE) in dogs. DESIGN: Retrospective cohort study. ANIMALS: 25 dogs with GME and 18 dogs with NE (diagnosis confirmed in 8 and 5 dogs, respectively). PROCEDURES: Records of dogs with GME or NE were reviewed for results of initial neurologic assessments and clinicopathologic findings, treatment, follow-up clinicopathologic findings (for lomustine-treated dogs), and survival time. Dogs with GME or NE treated with lomustine and prednisolone were assigned to groups 1 (n = 14) and 3 (10), respectively; those treated with prednisolone alone were assigned to groups 2 (11) and 4 (8), respectively. RESULTS: Prednisolone was administered orally every 12 hours to all dogs. In groups 1 and 3, mean lomustine dosage was 60.3 mg/m(2), PO, every 6 weeks. Median survival times in groups 1 through 4 were 457, 329, 323, and 91 days, respectively (no significant difference between groups 1 and 2 or between groups 3 and 4). Within the initial 12 months of treatment, median prednisolone dosage was reduced in all groups; dosage reduction in group 1 was significantly larger than that in group 2 at 6, 9, and 12 months. Combination treatment most frequently caused leukopenia, but had no significant effect on liver enzyme activities. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs with GME and NE, oral administration of lomustine and prednisolone or prednisolone alone had similar efficacy. Inclusion of lomustine in the treatment regimen was generally tolerated well.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
05 Veterinary Medicine > Department of Clinical Research and Veterinary Public Health (DCR-VPH) > Experimental Clinical Research 05 Veterinary Medicine > Department of Clinical Veterinary Medicine (DKV) > DVK - Clinical Research [discontinued] 05 Veterinary Medicine > Department of Clinical Veterinary Medicine (DKV) > DKV - Clinical Neurology |
UniBE Contributor: |
Oevermann, Anna, Doherr, Marcus, Henke, Diana |
ISSN: |
0003-1488 |
Publisher: |
American Veterinary Medical Association |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:31 |
Last Modified: |
05 Dec 2022 14:10 |
Publisher DOI: |
10.2460/javma.238.3.337 |
Web of Science ID: |
000286642800042 |
URI: |
https://boris.unibe.ch/id/eprint/12060 (FactScience: 218337) |
Actions (login required)
 |
Edit item |